The new CEO of pharmaceutical firm GlaxoSmithKline ( GSK ) , alongside Walmsley , will receive a pay deal worth 25 % less than that of her predecessor , Sir Andrew Witty . Walmsley , who will become the pharmaceutical industry ’s most powerful woman when she takes up her post next month , will potentially receive £ 8.8 m ( $ 10.8 million ) a year , compared to Witty ’s maximum £ 11.6 ##m . investors claimed that Walmsley ’s reduced pay was due to her being less experienced than Witty . The firm also stated that investors wanted to see increases in relation to executive pay .
The new CEO of pharmaceutical firm GlaxoSmithKline (GSK), Emma Walmsley, will receive a pay deal worth 25% less than that of her predecessor, Sir Andrew Witty. Walmsley, who will become the pharmaceutical industry’s most powerful woman when she takes up her post next month, will potentially receive £8.8m ($10.8m) a year, compared to Witty’s maximum £11.6m. GSK claimed that Walmsley’s reduced pay was due to her being less experienced than Witty. The company also stated that investors wanted to see restraint in relation to executive pay.